Gastroesophageal reflux disease (GERD) is a very common gastrointestinal disorder worldwide and a significant problem that affects quality of life and the ability to perform daily activities [1]. Reflux of gastric contents into the esophagus causes an uncomfortable condition with symptoms such as heartburn, regurgitation, chest pain, difficulty swallowing, and a chronic cough [2]. Lower esophageal sphincter malfunction, esophageal motility disorders, slowed stomach emptying, obesity, and diet and lifestyle contribute to the condition. GERD has been on the rise in recent years around the world, especially in the developing world, because of a change in lifestyle, high obesity rates, and a sedentary lifestyle [3,4]. GERD has a profound impact on physical, emotional, and social health. Sleep disturbances, decreased work productivity, and impaired daily functioning are common problems among patients. Chronic reflux can also cause complications such as erosive esophagitis, Barrett's esophagus, esophageal strictures, and esophageal adenocarcinoma. So early diagnosis and successful management are imperative to minimize morbidity and enhance patient outcomes [5]. Usually, GERD is diagnosed based on clinical history and symptoms and may be confirmed by upper gastrointestinal (UGI) endoscopy, pH monitoring, or a response to acid-suppressive drugs. Common symptoms include a feeling of heartburn and acid regurgitation at least twice a week. Endoscopy can be very helpful in diagnosing complications like erosive esophagitis or Barrett's esophagus. While lifestyle modification plays a strong role in treatment, it also involves smoking cessation, weight reduction, dietary changes, and avoiding late meals [6,7]. Proton pump inhibitors (PPIs) are thought to be the ideal treatment for GERD at present due to their powerful acid-inhibitory activity. They work by permanently blocking the hydrogen-potassium ATPase enzyme system in the gastric parietal cells, thereby decreasing acid production. The most frequently used PPIs are omeprazole, pantoprazole, esomeprazole, rabeprazole, and lansoprazole. PPIs relieve symptoms, heal erosive esophagitis, and improve quality of life in patients with GERD [8]. Several studies have shown that PPIs are more effective than H2 receptor antagonists and antacids in controlling GERD-related symptoms. Patients usually improve symptomatically within a couple of weeks of treatment. Some patients, however, do not respond completely or adequately to treatment because of poor compliance, high disease severity, obesity, or associated functional gastrointestinal disorders. Adverse effects are also a concern when using PPIs for a longer period of time, such as vitamin B12 deficiency, osteoporosis, renal impairment, and intestinal infection, but these are relatively infrequent [9]. Although the use of PPIs seems to be universal, there is a lack of local data on the therapeutic results of PPIs among patients with GERD in tertiary care units. Assessment of local populations' responses to PPI therapy is relevant to treatment patterns and patient management. Hence, this study was conducted to evaluate the clinical outcomes of proton pump inhibitor therapy in patients diagnosed with gastroesophageal reflux disease [10].

Study Design & Setting The present study was a descriptive cross-sectional study conducted in the Department of Gastroenterology, Ayub Teaching Hospital, Abbottabad, Pakistan, from July 2023 to December 2023. Participants Non-probability consecutive sampling was used to select 100 patients suffering from GERD. Patients between the ages of 18 and 65 of both sexes presenting with heartburn, regurgitation, or epigastric discomfort were included. Diagnosis was made by clinical examination and, if necessary, upper gastrointestinal endoscopy. Sample Size Calculation The sample size of 100 patients was determined using the WHO sample size calculator, with a 95% confidence interval, a 5% margin of error, and an expected 50% rate of symptomatic improvement in GERD patients treated with proton pump inhibitors, as seen in previous regional and international studies. Inclusion Criteria • Patients aged 18–65 years • Both male and female patients • Clinically diagnosed cases of GERD were selected as the dependent variable. • Patients who are willing to participate in the study • Patients on proton pump inhibitor (PPI) medication Exclusion Criteria • Patients with peptic ulcer disease. • Patients who have gastrointestinal malignancy • Pregnant females • Mining the literature on gastrointestinal surgery. Literature review of gastrointestinal surgery. • Hepatic or renal failure • Patients unwilling to participate Diagnostic and Management Strategy Diagnosis for GERD was made on clinical grounds with upper gastrointestinal endoscopy as appropriate. Patients who were enrolled in the study were all prescribed standard-dose proton pump inhibitors (PPIs) for 8 weeks and educated about lifestyle modification, including diet, smoking cessation, and late-night meals. Statistical Analysis The data were entered and analyzed using SPSS version 26. Quantitative variables, such as age, were reported as mean ± standard deviation, and qualitative variables as frequencies and percentages. The chi-square test was applied to determine the symptom improvement pre- and post-treatment. A p-value ≤0.05 was considered statistically significant. Ethical Approval Ethical approval for this study was obtained from the Institutional Review Board/Ethical Committee of the respective hospital and medical college before data collection. Written informed consent was obtained from all participants. Confidentiality and anonymity of patient information were strictly maintained throughout the study in accordance with ethical research guidelines and the Declaration of Helsinki.

A total of 100 patients diagnosed with gastroesophageal reflux disease were included in the study. Among them, 58 (58%) were males, and 42 (42%) were females. The mean age of the participants was 41.6 ± 12.4 years, with the majority of patients aged 31–50 years. Heartburn was the most common presenting symptom, observed in 88% of patients, followed by regurgitation in 74% and epigastric discomfort in 61%. Following eight weeks of proton pump inhibitor therapy, significant symptomatic improvement was observed in the majority of participants. Heartburn improved in 82% of patients, regurgitation in 76%, and epigastric discomfort in 71%. Complete symptom resolution was achieved in 64 patients, while 24 patients showed partial improvement. Twelve patients demonstrated minimal or no response to therapy. Patients with shorter disease duration and better adherence to lifestyle modifications showed a greater therapeutic response than those with chronic symptoms and poor compliance. Statistical analysis demonstrated a significant reduction in symptom severity scores after treatment (p=0.001). No serious adverse drug reactions were observed during the study period, and proton pump inhibitor therapy was generally well tolerated among study participants.

Table 1: Demographic Characteristics of Study Participants (n=100)

Table 1 demonstrates the demographic distribution of GERD patients enrolled in the study. Male patients were predominant, and the majority of participants belonged to the 31–50 years’ age group.

Table 2: Baseline Clinical Presentation of GERD Patients

Table 2 presents the baseline clinical symptoms among patients with gastroesophageal reflux disease. Heartburn was the most frequently reported symptom, followed by regurgitation and epigastric discomfort.

Table 3: Symptomatic Improvement After Proton Pump Inhibitor Therapy

Table 3 shows the therapeutic response following eight weeks of proton pump inhibitor therapy. Significant improvement was observed in major GERD symptoms, with statistically significant p-values.

Table 4: Overall Treatment Outcome Following PPI Therapy

Table 4 illustrates the overall clinical outcome after proton pump inhibitor therapy. Most patients achieved complete symptom resolution, while only a small proportion showed minimal or no improvement. Mild adverse effects were infrequent.

The present study compared the clinical effects of proton pump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) and showed that PPI therapy is clinically effective. After 8 weeks of therapy, the majority of patients had improved relief of heartburn, regurgitation, and epigastric discomfort, which further indicated that PPIs are the primary therapy for GERD. Most patients had full resolution of their symptoms, while a minority had minimal or no improvement. These results are consistent with recent international research showing the benefits of PPI therapy in the treatment of GERD [11,12]. In this study, 82 percent of patients with heartburn and 76 percent of patients with regurgitation experienced symptom improvement. A similar study of PPI treatment for GERD showed that about 78% of patients significantly resolved their symptoms. Comparable response rates are observed across the PPIs, suggesting they are also very effective in regular clinical practice, across various populations and healthcare settings [13]. The mean age of the patients in our study was 41.6 ± 12.4 years, with more male than female participants. These trends were also observed in more recent GERD studies from 2021, with the middle-aged adult population most affected. The rise in prevalence in this age group could be linked to obesity, eating behaviors, smoking, stress, and low levels of physical activity. These results also corroborate the increased prevalence of GERD in the adult population in developing countries [14,15]. Our results also showed a statistically significant decrease in symptom severity post-therapy (p=0.001). A meta-analysis found that optimized PPI dosing led to better outcomes and symptom control of GERD. Likewise, another recent review highlighted that PPIs continue to provide excellent acid suppression and mucosal healing in both erosive and non-erosive reflux disease [16]. In our study, early disease onset was associated with a better response to therapy than chronic disease onset. This observation is consistent with current evidence that early diagnosis and timely treatment are associated with better treatment outcomes and lower complication rates. If treatment is delayed, it can result in ongoing mucosal injury, esophageal dysmotility, and decreased sensitivity to PPIs at standard doses [17]. While PPIs are still highly effective, newer acid-inhibitory drugs have been investigated in recent literature, such as potassium-competitive acid blockers (P-CABs), including monoprint. Several studies published in the past five years have suggested that P-CABs may offer more rapid and greater acid suppression in severe erosive esophagitis. Nevertheless, PPIs are still the preferred drug because they are known to be effective, low-cost, and have an acceptable safety profile. A recent cost-effectiveness analysis also found that PPIs remain more cost-effective than newer options for the routine management of GERD [18]. We did not observe any serious adverse effects in our study, and treatment was well tolerated. Recent evidence-based reviews have highlighted the safety and efficacy of short-term PPI therapy in patients with GERD, and similar findings were reported here. However, recent research has cast doubt on the safety of long-term PPI usage and possible links to gastric cancer, deficiencies in nutrients, renal disease, and infections. These concerns are predominantly regarding long-term therapy and highlight the need to use PPIs on clinical indications and for time-limited therapy [19].In general, the results of the present study are consistent with the most recent national and international studies, which have shown that PPIs are both helpful and effective in the symptomatic management of GERD and should be the first-line treatment for GERD. Appropriate use of PPIs, patient education, lifestyle modification, and early diagnosis can have a major impact on clinical outcomes and the quality of life of GERD patients [20]. Limitations The study was conducted at a single tertiary care hospital with a small number of patients, which may limit the generalizability of its results. Long-term therapeutic effects and side effects of proton pump inhibitors could not be evaluated due to the short follow-up period. Not all patients underwent endoscopic evaluation.

PPI treatment was found to be effective at improving GERD symptoms. Treatment resulted in significant improvement for most patients for heartburn, regurgitation, and epigastric discomfort. Prompt diagnosis, lifestyle modifications, and appropriate PPI use are significant strategies for improving clinical outcomes and quality of life in patients with GERD.

Disclaimer: Nil

Conflict of Interest: Nil

Funding Disclosure: Nil

Authors' Contributions

Concept & Design of Study: Hafizullah Khan, Syeda Anam Noor Kazmi, Prof. Adil Naseer Khan

Data Acquisition: Hafizullah Khan, Zabihullah

Data Analysis & Interpretation: Hafizullah Khan, Syeda Anam Noor Kazmi

Drafting of Manuscript: Hafizullah Khan,Muhammad Sarwar Khan

Critical Review & Intellectual Content: Syeda Anam Noor Kazmi, Zabihullah, Prof. Adil Naseer Khan

Final Approval of the Version to be Published: All authors reviewed and approved the final version of the manuscript and agree to be accountable for all aspects of the work in accordance with the ICMJE authorship criteria.